AHA: Arcoxia (etoricoxib) May Not Increase Risk of Cardiovascular Events
14th Nov 2006, 02:05 GMT
CHICAGO -- Arcoxia (etoricoxib), an investigational Cox-2 inhibitor, has a cardiovascular safety profile similar to diclofenac, an old line NSAID, according to pooled data on almost 35,000 arthritis patients.
AHA: Arcoxia (etoricoxib) May Not Increase Risk of Cardiovascular Events related news:
- MEDAL: Etoricoxib Shows Same Thrombotic Cardiovascular Risk as Diclofenac — Medscape Cardiology Headlines
- AHA: No Cardiovascular Benefit from Folic Acid and B Vitamins — MedPage Today Cardiovascular
- National US Program Gets Americans Dancing for Heart Health — Cardiology News from StratCenter.com
- AHA: Women Receive Less Cardiovascular Secondary Prevention — MedPage Today Cardiovascular
- Study Confirms Folic Acid, B Vitamins Do Not Prevent Cardiovascular Events — Medscape PublicHealth Headlines
- Merck: New pain killer safer than Vioxx — Business and financial news - CNNMoney.com
- Merck says new drug is safer than Vioxx — Cardiology News from StratCenter.com
- Merck: New pain drug safer than Vioxx — Financial news of the day - CNNMoney.com
- Merck: New drug safer than Vioxx — Business and financial news - CNNMoney.com
- Diabetes drug may reduce cardiovascular risks — EurekAlert! - Medicine and Health